A Multi-center, Open-label Study Of Cp-690,550 In Subjects With Moderate To Severe Ulcerative Colitis

Trial Profile

A Multi-center, Open-label Study Of Cp-690,550 In Subjects With Moderate To Severe Ulcerative Colitis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions
  • Acronyms OCTAVE; OCTAVE Open
  • Sponsors Pfizer
  • Most Recent Events

    • 13 Jul 2017 According to a Pfizer media release, the supplemental New Drug Application (sNDA) for XELJANZ for adult patients with moderately to severely active ulcerative colitis (UC), has been accepted for filing by the U.S. Food and Drug Administration (FDA). The FDA has provided an anticipated Prescription Drug User Fee Act (PDUFA) action date in March 2018 for the sNDA. Data from OCTAVE Induction 1, OCTAVE Induction 2, OCTAVE Sustain and OCTAVE Open studies supported the application.
    • 15 Jul 2016 Planned primary completion date changed from 1 May 2016 to 1 Jul 2018.
    • 02 Nov 2015 Planned number of patients changed from 725 to 900, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top